BCG lymphadenitis in an HIV-infected child 9.5 years after vaccination.
Complications of Bacillus Calmette-Guerin (BCG) vaccination have been reported in immunocompetent as well as in immunocompromised individuals. Severe and/or late complications have been associated with impairment of cell-mediated immunity. A case of BCG lymphadenitis in a vertically infected HIV-positive boy 9.5 years after vaccination is presented. The vaccination was performed within the first week of life, the HIV status of the mother being unknown. When the boy was 2.5 years old, his HIV infection was diagnosed after his mother had died from AIDS. At that time his CD4 count was 739 cells/microL. In the course of the following years, his CD4 count declined steadily, until it reached a low of about 20 cells/microL at the age of 5.5 years. He was troubled with recurring respiratory infections and one incidence of severe pancreatitis. Apart from that, he was in stable condition and led a more or less normal life. At the age of 9.5 years he developed lymphadenitis in his left axilla. The node was examined via biopsy, and the appropriate tests showed an infection with Mycobacterium bovis BCG variety. The CD4 count at that time was 16 cells/microL, polymerase chain reaction showed 220,000 RNA copies/mL. There were no signs of dissemination. Antitubercular agents were administered, and an antiretroviral combination therapy was started. The patient was discharged from the hospital after approximately 2 months. After an uneventful period of 9 months, the boy, still on antitubercular medicine, exhibited a secreting fistula in his left axilla, again due to Mycobacterium bovis, BCG variety. The fistulous tissue was removed surgically, and the antitubercular treatment was given intravenously for almost 3 months before being changed to an oral application. In addition, the antiretroviral regimen was completely exchanged. The case presented illustrates that there is a risk of very late complications in HIV-infected individuals, even when they are vaccinated when they are asymptomatic newborns. Although the risk seems low, one has to be aware of the problem because timely treatment is probably essential to prevent dissemination of the infection. Late complications of BCG vaccinations are most likely to be detected in countries with high medical standards, where HIV-infected children are surviving for longer periods of time.
Hofstadler
G
G
Landeskinderklinik Linz, Linz, Austria. ghofstadler@msn.com
Schmitt
K
K
Tulzer
G
G
Binder
L
L
Brandstetter
B
B
D000995:Antitubercular Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000009:adverse effects*; D002648:Child; D006679:HIV Seropositivity; D006801:Humans; D008199:Lymphadenitis / Q000139:chemically induced*; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology / Q000302:isolation & purification*; D014376:Tuberculosis / Q000188:drug therapy / Q000382:microbiology*
D000995:Antitubercular Agents; D001500:BCG Vaccine